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Pulmonary embolism (PE) encompasses a wide spectrum of
clinical presentations. Many patients with PE remain in en-
tirely stable condition, with normal systemic arterial pressure
and right ventricular function. Such patients have a good
prognosis with anticoagulation alone and can often be man-
aged by general internists without subspecialty consultation.
Rarely, patients with PE will present in cardiogenic shock due
to right heart failure. They are gravely ill and require prompt
and definitive diagnostic testing and intervention. Thromboly-
sis, embolectomy or inferior vena cava filter placement in
conjunction with anticoagulation are often necessary to pre-
vent recurrent PE or death. Between these extremes lies a
large group of patients characterized by the combination of
normal systemic arterial pressure and pulmonary hypertension
due to increased right ventricular afterload. Their optimal
management is highly controversial. Such patients may appear
to be in deceptively stable condition because their blood
pressure and heart rate, at least initially, remain normal.
At times, acute right ventricular dysfunction in patients with
PE can be readily detected by physical examination. Bulging
neck veins with v waves, a left parasternal lift and a systolic
murmur at the left lower sternal border that increases in
intensity during inspiration are important clues to the presence
of acute tricuspid regurgitation. Often, these signs will be
obscured by obesity, a barrel chest with increased anteropos-
terior diameter or a very noisy emergency department or
intensive care unit.
Other signs to identify these patients with PE and right
ventricular dysfunction require additional testing. The electro-
cardiogram (ECG) may demonstrate a new right bundle
branch block or right-axis shift, indicative of right heart strain.
Particularly useful and an even more common finding is T
wave inversion in the anterior precordial leads (1). The chest
radiograph may show enlargement (.16 mm) of the right
descending pulmonary artery (2). However, the most sensitive
tool for diagnosing acute cor pulmonale is the echocardiogram
(3), which may exhibit pulmonary artery hypertension with
Doppler flow velocity recordings in the right ventricular out-
flow tract, right ventricular enlargement, septal flattening and
paradoxic septal motion or diastolic left ventricular impair-
ment. The McConnell sign, a distinct echocardiographic pat-
tern of regional right ventricular dysfunction in which the apex
is spared, appears to be specific for acute PE (4). Thus,
identification of patients with PE with right ventricular dys-
function will often require input from a cardiovascular subspe-
cialist.
Once identified, patients with PE and right ventricular
dysfunction require close monitoring and decisive therapy.
Results from a trial (5) of 101 initially normotensive patients
with PE suggest that in the absence of contraindications, they
may benefit from thrombolytic therapy. Among patients ran-
domized to receive recombinant tissue-type plasminogen acti-
vator (100 mg/2 h) followed by heparin, none died or had
recurrent PE. In contrast, among the 55 patients assigned to
receive heparin alone, 5 had recurrent PE despite therapeutic
levels of anticoagulation (p 5 0.06), and recurrent PEs were
fatal in 2 of these 5. All five adverse clinical outcomes occurred
in heparin-alone treated patients who presented with the
combination of normal systemic arterial pressure plus right
ventricular hypokinesia on echocardiography. Echocardiogra-
phy in normotensive patients with PE is especially important
when lung perfusion defects involve .30% of the lung fields on
nuclear scan (6). With increasingly large perfusion defects on
scanning, the likelihood of right ventricular failure increases.
The Management Strategy and Prognosis of Pulmonary
Embolism Registry (MAPPET), reported on in this issue of the
Journal (7), undertook an ambitious 16-month study of pa-
tients with PE and right ventricular dysfunction in 204 German
centers. A total of 1,001 patients were enrolled, thus making it
a landmark as the largest registry of PE in patients with
hemodynamic impairment (7). The investigators’ sister report
(8) on the impact of thrombolytic therapy among hemodynam-
ically stable patients with major PE is also a most valuable
contribution. Taken together, these two reports provide crucial
data in a field that has until now relied too much on oratory.
In the MAPPET study, the traditional, rigid approach of
ventilation–perfusion lung scanning followed by pulmonary
angiography was replaced by a more flexible diagnostic algo-
rithm in which echocardiography was performed in 75% of
patients. In the MAPPET study, 75% of patients were inves-
tigated for deep venous thrombosis (with venous ultrasound or
contrast phlebography) as a surrogate for PE. In contrast, only
57% underwent lung scanning, and only 23% of MAPPET trial
patients underwent pulmonary angiography.
The most important message from the MAPPET study is
that PE associated with right ventricular dysfunction is fre-
quently lethal. The overall in-hospital mortality rate was 22%,
and almost all the deaths were due to PE. Among patients who
remained normotensive at the time of enrollment in MAPPET,
8% died, and 14% had recurrent, nonfatal PE. These data
contrast with the American experience in the Prospective
Investigation of Pulmonary Embolism Diagnosis (PIOPED)
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(9), which enrolled primarily hemodynamically stable patients
in whom the in-hospital mortality rate was 9.5%. Only 25% of
these deaths were ascribed to PE. Within the first week of the
hospital period, the recurrence rate of PE was only 4%.
Therefore, before the MAPPET study, which focused on
patients with right ventricular dysfunction, PE was considered
a disease in which a benign outcome was almost always assured
as long as the diagnosis of PE was established and adequate
anticoagulation was administered. Naturally, with this mindset,
the rationale for intervention with thrombolysis or embolec-
tomy was seldom compelling.
The contrast between the MAPPET and PIOPED studies
underscores the importance of recognizing the spectrum of
severity of PE. Risk stratification of patients with PE is
paramount because optimal management depends on progno-
sis. With the identification of right heart failure, which can be
rapidly confirmed with echocardiography, patients with PE
with a potentially ominous outcome can be rapidly identified.
These patients merit aggressive intervention by subspecialists
skilled in thrombolysis, embolectomy and vena cava interrup-
tion.
With regard to management of patients with PE in hemo-
dynamically stable condition who have right ventricular dys-
function, the sister publication of the MAPPET study (8)
describes the 719 registry patients who presented without
cardiogenic shock. Thrombolytic therapy was initially admin-
istered to 169 patients (23.5%), whereas the remaining 550
received heparin alone. (Subsequently, an additional 125
(23%) patients who received heparin alone were crossed over
to thrombolysis during the hospital period.) Thirty-day mor-
tality (4.7% vs. 11.1%) and recurrence of PE (7.8% vs. 21.9%)
were markedly reduced among those patients who received
initial thrombolysis. On multivariate analysis, only thromboly-
sis was found to be an independent predictor of survival, with
an odds ratio for in-hospital death of 0.46. The price paid for
this improved outcome was a threefold increase in major
bleeding episodes among those receiving thrombolysis (21.9%
vs. 7.8%).
Although no large randomized, controlled trial exists to
substantiate or refute the MAPPET experience, these data
provide evidence in favor of primary dissolution of thrombus in
the presence of PE with right ventricular dysfunction. When
thrombolysis is contraindicated, embolectomy either with
catheter-based techniques (10) or operation (11) should be
considered. To maximize the likelihood of survival, it is
crucially important to decide quickly whether to proceed with
intervention, without waiting until the patient with PE devel-
ops overt cardiogenic shock. Fortunately, the task of rapid
triage and risk stratification can be accomplished expeditiously
and noninvasively with transthoracic echocardiography.
In summary, the MAPPET study indicates that many pa-
tients with PE can benefit from the expertise of cardiovascular
specialists: 1) Cardiologists may quickly recognize the some-
times subtle signs of right heart failure on physical examina-
tion. 2) Cardiologists will be especially attuned to ECG
manifestations of right heart strain. 3) Noninvasive cardiolo-
gists can perform and interpret echocardiograms to aid in the
diagnosis and risk stratification of PE. 4) Because of their
thorough familiarity with thrombolytic agents for the treat-
ment of acute myocardial infarction, cardiologists are well
equipped to screen patients with PE for potential bleeding
complications and contraindications to lytic therapy. 5) Inter-
ventional cardiologists may be qualified to perform suction
catheter embolectomy. 6) Cardiologists can function as liaisons
to their cardiac surgical colleagues for prompt referral of
appropriate candidates for open surgical embolectomy and can
assist in their postoperative management. The MAPPET study
will serve the cardiovascular community well by reminding us
of our useful roles in managing patients with PE and right
ventricular dysfunction.
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Abbreviations and Acronyms
ECG 5 electrocardiogram, electrocardiographic
MAPPET 5 Management Strategy and Prognosis of Pulmonary
Embolism Registry
PE 5 pulmonary embolism
PIOPED 5 Prospective Investigation of Pulmonary Embolism
Diagnosis
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